Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation

Core Insights - Jasper Therapeutics reported positive preliminary clinical data from the ETESIAN Phase 1b study of briquilimab, showing significant reductions in airway hyperresponsiveness and eosinophilic response in asthma patients [2][4][5] Group 1: ETESIAN Study Findings - A single subcutaneous 180mg dose of briquilimab resulted in substantial reductions in sputum eosinophils at both 6 weeks (1.88% to 0.44%) and 12 weeks (1.88% to 0.38%) [2][12] - Improvements in FEV1 were observed in both Early Asthmatic Response (EAR) and Late Asthmatic Response (LAR), with LAR %Max FEV1 improving by 10.4% at 6 weeks and 8.7% at 12 weeks compared to baseline [7][10] - The study demonstrated a favorable safety profile for briquilimab, with no dose-limiting toxicities and infrequent low-grade adverse events [14] Group 2: BEACON Study Investigation - Jasper completed an internal investigation into the lack of clinical response in the BEACON study, concluding that the unexpected results were likely due to patient selection issues rather than problems with the drug product [3][16] - The investigation revealed that 9 out of 10 patients did not have chronic spontaneous urticaria (CSU) as their symptoms were not mast cell-driven, which affected the efficacy results [16][17] - The company is confident that insights from this investigation will help minimize enrollment of patients without mast cell-driven diseases in future studies [17] Group 3: Future Developments - Jasper plans to further develop briquilimab for asthma treatment, supported by the positive data from the ETESIAN study and the favorable safety profile observed [4][20] - The company anticipates additional data from the BEACON study in Q1 2026, which will inform dose selection for the Phase 2b CSU study planned for mid-2026 [17][20]